Mayo Clinic expert offers perspective on experimental Alzheimer's disease drug

According to drugmakers Eisai and Biogen, a Phase 3 clinical study on a potential new Alzheimer's disease drug shows promise. The study findings show that the drug, lecanemab, reduced clinical

Related Keywords

China ,Japan ,Ronald Petersen ,Mayo Clinic Alzheimer Disease Research Center ,Drug Administration ,Clinical Trials On Alzheimer Congress ,Mayo Clinic ,Disease Research ,Clinical Trials ,Health ,